Compare Amylx Pharmaceuticals Inc (AMLX) vs Appian Corp (APPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Appian Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Appian Corp trades at $35.5 (market cap $2.54B). The key difference: Amylx Pharmaceuticals Inc and Appian Corp are close in size by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.
| AMLX | APPN | |
|---|---|---|
Market Cap | $2.64B | $2.54B |
Sector | Health | Technology |
52-Week High | $24.19 | $45.64 |
52-Week Low | $7.82 | $18.72 |
Enterprise Value | $2.39B | $2.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Appian (APPN) trades at $34.82, down 2.14% on the day despite strong technical momentum. The stock shows bullish moving average signals but overbought RSI readings. Fundamentally, the company delivered three consecutive earnings beats with Q2 2026 EPS of $0.13 beating expectations of $0.00308, while revenue grew 19% year-over-year to $203.3 million. Recent news highlights AI-powered underwriting partnerships and strong enterprise demand driving growth.
Appian presents a mixed investment case with strong revenue growth and AI momentum offset by negative profitability metrics and elevated valuations. The stock trades above analyst consensus target of $32.50, suggesting limited near-term upside. Key risks include persistent negative ROE (-936.62%) and high debt levels, though improving cash flow and AI adoption provide growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →
